Introduction
Hyperkalemia is a common life-threatening condition that often complicates the management of heart failure (HF) and chronic kidney disease (CKD) [1, 2] . This issue is increasingly evident with the greater use of renin-angiotensin-aldosterone system (RAAS) inhibitors, which have been shown to improve survival in patients with HF [3] [4] [5] and decrease proteinuria and the slow progression of CKD [6] [7] [8] . Moreover, optimal RAAS inhibitor dosing has been associated with enhanced survival and lower medical costs compared with suboptimal dosing in observational studies [9] [10] [11] . Despite their life-prolonging and disease-modifying effects, RAAS inhibitor use is often limited to less than maximal doses or discontinued due to the development of hyperkalemia [12] [13] [14] [15] .
Patiromer (Veltassa ® ; Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA) is a sodiumfree, nonabsorbed, potassium-binding polymer approved for the treatment of hyperkalemia in the United States; it recently was also approved in the European Union [16, 17] . In the OPAL-HK trial, patiromer reduced serum potassium levels in CKD patients receiving RAAS inhibitors who developed mild or moderate-to-severe hyperkalemia [18] . In a subsequent randomized withdrawal phase among patients with normalized serum potassium, patiromer was significantly more effective than placebo in preventing recurrence of hyperkalemia ( p < 0.001); consequently, 94% of patiromer-treated patients remained on RAAS inhibitor therapy compared to 44% of patients in the placebo group [18] . Comparable results were seen in a prespecified analysis of hyperkalemic HF patients participating in OPAL-HK [19] . In the AMETHYST-DN trial, the efficacy and safety of patiromer in maintaining serum potassium were observed over 52 weeks in outpatients with diabetes mellitus, CKD, and hypertension who had hyperkalemia on RAAS inhibitor therapy [20] . Patients in the aforementioned clinical studies received patiromer with food in a twice-daily (BID) dosing regimen [18, 20] . Here, we report results from the TOURMALINE study, which was designed to compare the efficacy and safety of patiromer given once daily (QD) without food versus with food for the treatment of hyperkalemia.
Methods

Study Oversight
The protocol was approved by a central institutional review board. All patients provided written informed consent; the study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines.
Study Population
Adult patients ( ≥ 18 years old) with hyperkalemia (defined as 2 local potassium values >5.0 mEq/L; each obtained from separate venipunctures in different arms, when possible) were eligible. Patients receiving RAAS inhibitors, beta blockers, or diuretics were required to be on stable doses for at least 14 days prior to screening, and any concomitant medications taken consistently had to be given QD or BID. Patients could have clinically stable CKD, HF, diabetes mellitus (type 1 or 2), and/or hypertension, but none of these disorders was a requirement for study entry.
Key exclusion criteria included major organ transplantation, dialysis or expected need for dialysis, cardiovascular event or intervention within 3 months before screening, hemodynamically unstable arrhythmia, hospitalization for HF within the previous 3 months, and poorly controlled diabetes mellitus or blood pressure. Patients who received treatment with calcium or potassium supplementation or sodium or calcium polystyrene sulfonate within 7 days before screening were also excluded.
Study Design and Procedure
This was an open-label study conducted at 29 sites in the United States in which eligible patients were randomized in a 1: 1 ratio to receive patiromer QD either without food or with food ( Fig. 1 ) . Patients who were hyperkalemic at the screening visit -defined as serum potassium levels >5.0 mEq/L in both of the screening samples measured by point of care device (iSTAT; Abbott Point-ofCare, Princeton, NJ, USA) and who met all other eligibility criteria, fasted overnight (water was permitted) and returned the next day for the baseline visit (day 1). The morning of the baseline visit (day 1), patients were randomized and blood samples were obtained immediately before the initial 8.4 g dose of patiromer (baseline/hour 0). Patients began their randomly assigned patiromer dosing on day 2. Patients randomized to the with-food group were instructed to take patiromer from initiation to within 30 min after finishing a meal or other food; patients randomized to the without-food group were instructed to take patiromer at least 1 h before or 2 or more hours after eating a meal or other food. Patients were instructed to take concomitant oral medications at least 6 h before the first dose of patiromer (per the label instructions at the time). Thereafter, patients were instructed to take their patiromer dose around ( without-food group) or with ( with-food group) a specific meal, which was chosen by each patient so that the patiromer dose was taken separate from their daily or twice daily concomitant oral medications. Patients recorded the time when patiromer was taken and the time when food was eaten in a daily diary for the duration of the study. Patients were allowed to continue their usual diets without study-prescribed dietary counseling.
Following day 1, randomized patients attended scheduled study visits on day 3, and then weekly at 1, 2, 3, and 4 weeks after starting patiromer treatment. For safety, patients were followed for 2 weeks after the last dose of patiromer (2 visits).
Potassium levels were measured by both local and central laboratories at each scheduled visit. Central laboratory measurements were used for assessments of efficacy and safety. The local potassium measurement was obtained by iSTAT Point-of-Care device. Local measurements were used for study entry criteria, dose titration, and safety assessments at study sites. During the study, patiromer daily doses could be increased or decreased by 8.4 g/day to a maximum of 25.2 g/day according to a prespecified titration schedule to achieve and maintain potassium levels within the target range of 3.8-5.0 mEq/L ( Table 1 ) .
Study Endpoints
The primary efficacy endpoint was the proportion of patients with serum potassium in the target range (3.8-5.0 mEq/L) at either week 3 or 4. The secondary efficacy endpoint was the treatment group difference in serum potassium change from baseline to week 4. Safety variables consisted of all adverse events (AEs); clinical laboratory test results (including serum potassium, calcium, and magnesium); vital signs (including blood pressure); and early withdrawal data.
Statistical Analysis
The efficacy and safety populations included all patients who were randomized and had taken at least one dose of patiromer. For the primary efficacy analysis, the proportion of responders (patients with serum potassium in the target range [3.8-5 .0 mEq/L] at either week 3 or 4) and its 95% CI were obtained using the Exact (ClopperPearson) method. No statistically significant difference between treatment groups was to be concluded if the CIs overlapped. The proportion of responders in prespecified subgroups by baseline serum potassium (<5.5 or ≥ 5.5 mEq/L), race (white vs all other), estimated glomerular filtration rate (eGFR; ≥ 30 or <30 mL/min/1.73 m 2 ), and diabetes mellitus (yes vs. no) was analyzed similarly.
The secondary efficacy analysis of mean change in serum potassium from baseline to week 4 used a parallel-lines analysis of covariance model to estimate the difference between treatment groups. The model included treatment group, baseline serum potassium as a continuous covariate, and race and history of diabetes mellitus as categorical covariates. The same analysis of covariance model was also used to evaluate the mean change in serum potassium from baseline to each visit during treatment, and from endof-treatment to last available follow-up visit.
For all analyses, descriptive statistics were summarized as mean and SE for continuous variables or proportions for categorical variables. Baseline demographic and clinical characteristics were summarized as mean and SD. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA), with statistical significance set at p < 0.05.
Results
Patient Disposition
Overall, 114 patients were randomized to patiromer without food ( n = 57) or with food ( n = 57). Of these, 103 patients (90%) completed the study ( Fig. 2 ) ; reasons for early study termination included AEs ( n = 3) investigator's decision ( n = 3), withdrawal by patient ( n = 3), lost to follow-up ( n = 1), and other reason ( n = 1; patient did not disclose taking prohibited medications). One patient in the with-food group did not receive any patiromer dose and was excluded from the efficacy and safety analyses. A second patient in the with-food group had an important protocol deviation, had no post-baseline serum potassium, and was excluded from the efficacy analyses.
Baseline Demographics and Clinical Characteristics
Of 112 patients evaluable for efficacy, the majority were men (65.2%) and ≥ 65 years old (65.2%; Table 2 ). In this US study, 82.1% were white and 56.3% were Hispanic/Latino. Most of the patients had CKD (75.9%), predominantly stages 3b-5 (non-dialysis) (61.6%), hypertension (93.8%), and diabetes mellitus (82.1%). At CONSORT diagram. a Screen failure: patients who met all study entry criteria except for local potassium at the screening visit could be re-screened once. More than one reason for screening failure may have been reported for a patient. Re-screened patients that had the same screen failure reason were only counted once for that reason. Proceed to next weekly visit 3 1 The daily dose of patiromer was increased or decreased by 8.4 g during the treatment period to maintain serum potassium (measured locally) within the target range of 3.8-5.0 mEq/L. At day 3 visit, patiromer dose should have been decreased to 0 for a confirmed potassium <3.8 mEq/L. If patiromer dose required titration, then initiation of the titrated dose occurred at the next planned administration.
2 Dose titration was not required if the potassium decrease from the previous visit was ≥0.5 mEq/L. 3 Additional safety visits were at the discretion of the investigator; upon request, patients returned for a safety visit <72 h. Mandatory safety visits were required if local potassium was >6.0 mEq/L. If the dose was already 25.2 g/day (maximum dose) and the patient had a confirmed potassium >6.0 mEq/L, standard of care for hyperkalemia was applied at the investigator's discretion. 4 If the patiromer dose was already 25.2 g/day and the patient had a serum potassium ≥5.5 mEq/L, standard of care for hyperkalemia would be applied per the investigator's discretion and a safety visit may be scheduled within 72 h, also at the investigator's discretion.
The target serum potassium range was 3.8-5.0 mEq/L, and available doses for titration were: 0 g/day patiromer (no patiromer dispensed, minimum dose), 8.4 g/day, 16.8 g/day, 25.2 g/day (maximum dose). For all scheduled study visits (starting from day 3 and until the last visit before the end of treatment), titration instructions were identical between the with-and without-food treatment groups. In the prespecified subgroup analyses of the proportion of responders by serum potassium, race, eGFR, and diabetes mellitus, more than 78% of patients were responders across subgroups for each comparison, the 95% CI overlapped between the without-food and with-food groups ( Fig. 4 ) . Comparable 
Dosing and Titration
The mean (SE) duration of patiromer treatment was 26.0 (0.9) and 27.0 (0.7) days in the without-food and with-food groups, respectively. The median (Q1, Q3) daily dose was 8. 
Safety/Tolerability
Overall, 51 (45.1%) of 113 patients evaluable for safety had at least one AE during the study (24 [42.1%] in the without-food group and 27 [48.2%] in the with-food group). The most common AEs (occurring in ≥ 3 patients overall) are shown in Table 3 ; these included mild diarrhea in 3 patients each in the without-food and withfood groups, mild-to-moderate constipation in 2 patients in each group, and mild increased creatine phosphokinase in 1 and 3 patients in these groups respectively. AEs considered by investigators to be related to patiromer were reported in 13 (11.5%) patients; the most common class of treatment-related AEs were gastrointestinal, occurring in 7 (6.2%) patients overall. Four patients had a total of 5 non-fatal serious AEs, none of which were deemed by investigators to be related to patiromer. These included 2 AEs of angina pectoris in one patient in the with-food group, and acute kidney injury in one patient in the without-food group; both patients were discontinued from the study. Two other patients in the without-food group had serious AEs that did not lead to interruption of patiromer dosing: intermittent claudication in one patient that resolved with treatment, and anemia in another patient that resolved without treatment. One death was reported; the patient, in the without-food group, died on study day 9 of cardiopulmonary arrest that was assessed by the investigator as not related to patiromer treatment. The patient had had type 2 diabetes mellitus, hypertension, and hypercholesterolemia and had missed the scheduled week 1 study visit due to hypoglycemia. The serum potassium measured at the last visit prior to death (day 3) was 5.1 mEq/L, down from 5.4 mEq/L at baseline. The safety review board assessed the death as related to cardiovascular causes (sudden cardiac death) and unlikely to be related to hypokalemia or hyperkalemia. Serum potassium remained ≥ 3.5 mEq/L in all patients. One patient (1.9%) in the without-food group experienced serum potassium ≥ 3.5 but <3.8 mEq/L. There were no AEs of hyperkalemia (serum potassium >5.0 mEq/L) throughout the study.
Mean (SE) serum calcium was 9.3 (0.6) mg/dL overall at baseline (9.3 [0.60] Prespecified abnormal laboratory values of serum magnesium <1.4 mg/dL occurred in 5 (4.5%) patients (3 in the without-food group and 2 in the with-food group); in 4 of these patients, serum magnesium was <1.8 mg/dL (lower limit of normal) at baseline. The serum potassium measurements were ≥ 4.4 and ≤ 5.0 mEq/L during the episodes of serum magnesium <1.4 mg/dL. In 2 patients (1.8%; one in each treatment group) with serum magnesium <1.4 mg/dL, hypomagnesemia of moderate severity was reported as an AE. The baseline serum magnesium levels were 1.9 and 1.6 mg/dL in these 2 patients. The lowest reported on-treatment magnesium value was 1.2 mg/dL. In both cases, patiromer was continued without a dose change and the AE resolved with over-the-counter magnesium replacement. An AE of mild decreased blood magnesium was reported in 1 (0.9%) patient (in the with-food group). The patient's serum magnesium was 2.1 mg/dL at baseline and the lowest on-treatment value was 1.6 mg/dL (at week 4 when the AE was reported). Patiromer treatment was completed without a dose change, and the patient completed follow-up with serum magnesium levels of 1.9 mg/dL (week 1 of follow-up) and 1.7 mg/dL (week 2 of follow-up).
There were no clinically relevant changes in vital signs or renal function laboratory parameters during the study.
Discussion
In this study, the primary endpoint (serum potassium in the range of 3.8-5.0 mEq/L at either week 3 or 4) was achieved by similar proportions of patients who received patiromer without and with food. Achievement of this endpoint was similar across the predefined subgroups of race, eGFR, and diabetes status. Patiromer treatment without food or with food resulted in similar reductions in the secondary endpoint of serum potassium at week 4. In addition, the proportion of patients achieving serum potassium in the target range was similar across all patient subgroups evaluated. In general, patients with higher baseline serum potassium values had greater reductions in serum potassium than patients who started treatment with lower baseline serum potassium values, a finding consistent across all patiromer trials [18] [19] [20] .
CKD and HF are highly prevalent disorders; this suggests that in an aging population, increasing numbers of patients will require treatment with RAAS inhibitors and, in turn, hyperkalemia may become an increasingly seen untoward event [21] [22] [23] . Current medical practice involves emergency treatment of acute, life-threatening hyperkalemia when observed, and often reducing RAAS inhibitor doses to prevent recurrences [1, 2] . However, RAAS inhibitor dose reduction or discontinuation is not ideal, and more options are needed to manage mild or moderate-to-severe hyperkalemia while potentially allowing continuation of these medications at optimal doses. The demonstration that patiromer is effective at reducing serum potassium, whether given without food or with food , may ease the medication adherence burden faced by many patients with complex medical conditions who require treatment for hyperkalemia.
Patiromer was well tolerated when administered without food or with food , and the safety profile was consistent with its known safety profile [16] [17] [18] [19] [20] . A similar proportion of patients experienced AEs across the 2 treatment groups. Hypokalemia was not observed in this study, and only 2 patients developed hypomagnesemia, which resolved with supplementation in both cases despite continued patiromer treatment. Patients with diabetes and those treated with loop diuretics or proton pump inhibitors are at an increased risk for hypomagnesemia, and therefore, clinicians should pay special attention to magnesium levels in such individuals. The prescribing information for patiromer recommends that magnesium supplementation be considered for patients who develop low serum magnesium levels during treatment [16] .
Study Limitations
This study was not designed as a true noninferiority comparison; rather, it was designed to determine if food appreciably changed the efficacy and/or safety of patiromer. Normally, food-medication interaction studies are small, and use pharmacokinetic comparisons based on serum drug levels. Subjects are often healthy volunteers who are generally given the study medication in both fasted and fed states to allow a generation of pharmacokinetic drug concentration-time profiles. Because patiromer is a nonabsorbed polymer, this type of formal pharmacokinetic analysis was not feasible. As such, we chose to study the therapeutic effect of patiromer on serum potassium levels when administered without food or with food to patients with hyperkalemia. The consistent findings observed in both the primary and secondary efficacy endpoints, the finding of similar efficacy across all prespecified subgroups, and the comparable safety profiles between the without-food and with-food groups suggest that neither food nor fasting affect the ability of patiromer to bind potassium within the gastrointestinal tract and lower abnormally elevated serum potassium.
In summary, patiromer is equally effective and well tolerated when taken without food or with food . These findings indicate the potential for dosing flexibility with patiromer.
